Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acu...
Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey
About this item
Full title
Author / Creator
Beguin, Y. , Selleslag, D. , Meers, S. , Graux, C. , Bries, G. , Deeren, D. , Vrelust, I. , Ravoet, C. , Theunissen, K. , Voelter, V. , Potier, H. , Trullemans, F. , Noens, L. and Mineur, P.
Publisher
England: Taylor & Francis
Journal title
Language
English
Formats
Publication information
Publisher
England: Taylor & Francis
Subjects
More information
Scope and Contents
Contents
Objectives:
We evaluated azacitidine (Vidaza
®
) safety and efficacy in patients with myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML), and chronic myelomonocytic leukaemia (CMML), in a real-life setting. Treatment response, dose, and schedule were assessed.
Methods:
This non-interventional, post-marketing survey include...
Alternative Titles
Full title
Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1656029267
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1656029267
Other Identifiers
ISSN
1784-3286
E-ISSN
2295-3337
DOI
10.1179/2295333714Y.0000000102
